AstraZeneca
12,032.00 GBpChange from previous close: −2.02%Absolute change: −248.00 GBp
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- £186.6B
- Enterprise value
- £217.92B
- P/E (trailing 12 months)
- 24.0
- Forward P/E
- 13.9
- PEG
- 1.16
- Price/book
- 495.6
- Price/sales
- 3.04
- EV/EBITDA
- 10.9
- EV/revenue
- 3.55
Profitability and growth
- Gross margin
- 81.7%
- Operating margin
- 23.5%
- Net margin
- 17.0%
- ROE
- 22.0%
- ROA
- 8.0%
- Revenue growth (year over year)
- 6.4%
- Earnings growth (year over year)
- 2.5%
Financial health
- Total cash
- £4.97B
- Total debt
- £32.35B
- Debt/equity
- 0.64
- Current ratio
- 0.89
- Quick ratio
- 0.66
Dividends
- Annual dividend per share
- 2.39 GBp
- Dividend yield
- 2.0%
- Payout ratio
- 47.4%
- Ex-dividend date
- August 6, 2026
Analysts and estimates
- Average price target
- 15,947.11 GBp
- Median price target
- 16,094.56 GBp
- High price target
- 20,289.44 GBp
- Low price target
- 11,949.82 GBp
- Analysts with a price target
- 23
- Consensus
- Buy
- Forward EPS
- 8.66 GBp
- EPS estimate, current year
- 10.26 GBp
Shares and trading
- Beta
- 0.21
- Average volume
- 3.39M
- Shares outstanding
- 1.55B
- Float
- 1.54B
- Institutional ownership
- 65.0%
- Insider ownership
- 0.1%